Royalty Report: Drugs, Pharmaceuticals, Blood Clotting – Collection: 26539

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Blood Clotting
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26539

License Grant
The Licensor entered into an agreement with Licensee for the discovery and development of aptamers.  

Under the terms of the agreement, the Licensee granted us a royalty-free, non-exclusive license under any inventions that the Licensee derives from the practice of the license that constitute  improvements to our technology for the purpose of conducting internal research and for any use outside of the field of the license we granted to the Licensee.

The Licensee has the exclusive right to discover, develop and commercialize products containing antidote-controlled aptamers  for the treatment of diseases related to the modulation of  fibrin depositions, platelet adhesion  and/or  platelet aggregation.

License Property
Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule. Aptamers are usually created by selecting them from a large random sequence pool, but natural aptamers also exist in riboswitches.
Field of Use
The rights granted apply to the medical research industry.

IPSCIO Record ID: 29007

License Grant
Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor's IP, to use, make, have made, import, sell, have sold and offer for sale Licensee's Products for all uses within the Field.
License Property
Parties desire to collaborate on the discovery, development, and commercialization of ARC 183 and potentially other anti-thrombin aptamers as human drug products.  ARC 183 means an Aptamer with a phosphor-backbone specifically composed of the following DNA sequence: GGTTGGTGTGGTTGG, wherein each nucleotide is a natural, unmodified, unsubstituted deoxyribonucleotide.  ARC 183 Patents means U.S. Patent No. 5,582,981, U.S. Patent No. 5,840,867 and U.S. Patent No. 5,756,291.  These patents are controlled by the licensee at the time of this agreement.
Field of Use
The use is for the modulation of blood clotting times in acute therapeutic applications through the use of Aptamers having a therapeutically useful level of anti-thrombin activity, including but not limited to coronary artery bypass graft surgery and percutaneous coronary intervention.

IPSCIO Record ID: 27922

License Grant
Licensor grants a worldwide, exclusive license, with the right to grant sublicenses, under the Licensor IP, to use, make, have made, import, sell, have sold and offer for sale Licensee Products for all uses within the Field.
License Property
Licensor possesses proprietary design expertise and know-how related to the discovery and identification of aptamers for drug development and with that technology has identified a preclinical drug development candidate, ARC 183.  ARC 183 means an Aptamer with a phosphor-backbone specifically composed of the following DNA sequence: GGTTGGTGTGGTTGG, wherein each nucleotide is a natural, unmodified, unsubstituted deoxyribonucleotide.   ARC 183 Patents means U.S. Patent No. 5,582,981; 5,840,867 and 5,756,291.
Field of Use
Licensee has technology and know-how and significant experience and expertise in the research and development of pharmaceutical products in the cardiovascular field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.